First-in-human trial targets aggressive triple-negative breast cancer with novel epigenetic approach
Telomir Pharmaceuticals (TELO) has reached a key milestone in its clinical development strategy after receiving FDA clearance for its Investigational New Drug (IND) application for Telomir-Zn, a novel therapy targeting advanced or metastatic triple-negative breast cancer (TNBC). The approval paves the way for the company to begin its first-in-human Phase 1/2 clinical trial in the first half of 2026, addressing a significant unmet need in one of the most aggressive and difficult-to-treat forms of breast cancer.
The IND clearance reflects the FDA’s review of a comprehensive data package, including pharmacology, toxicology, and manufacturing information, as well as encouraging preclinical results demonstrating activity in TNBC models. The upcoming study, known as TELO-001, will evaluate Telomir-Zn as an oral monotherapy, focusing on safety, tolerability, and early signs of efficacy in approximately 76 patients who have previously undergone systemic treatment.
The trial will be conducted in two phases. Phase 1 will determine the optimal dosage through a dose-escalation design, while Phase 2 will assess preliminary effectiveness, including response rates and survival outcomes. Importantly, the study will incorporate an advanced biomarker program to analyze how the drug impacts epigenetic regulation, gene expression, and cellular aging processes—areas believed to play a critical role in cancer progression.
Telomir-Zn represents a differentiated therapeutic approach, targeting intracellular metal balance and epigenetic mechanisms rather than relying on traditional chemotherapy or immunotherapy strategies. Preclinical data suggest the drug can influence gene expression and tumor biology by altering iron and zinc levels within cells, potentially improving genomic stability and slowing disease progression.
With triple-negative breast cancer accounting for approximately 10–15% of all breast cancer cases and often associated with poor outcomes, Telomir’s program enters a multi-billion-dollar market with limited treatment options. As the company moves into clinical evaluation, its innovative approach could open new pathways in oncology and broader age-related disease research.
You might like this article:Microsoft Earnings Highlight AI Strength and Cloud Momentum
